Sciomics GmbH

www.sciomics.de

Sciomics develops protein biomarker signatures for precision medicine with a focus on precision oncology, acute kidney injury and COVID-19 disease severity prediction.

About us

Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance.

At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform.

In the focus of our development activities are a biomarker signature for prediction and early diagnosis of peri-operative acute kidney injury as well as markers to predict a severe COVID-19 disease next to precision oncology.

In addition, we offer services based on our scioDiscover profiling platform and R&D collaborations for the discovery and validation of novel biomarkers, for drug target screening, and for the analysis of pathway activity as well as mode-of-action analyses.

Address
Sciomics GmbH
Karl-Landsteiner Str. 6
69151 Neckargemünd
Germany

Phone: +49 6221 4294830
Internet: www.sciomics.de

Contact person

Dr. Christoph Schröder
CEO
Phone: +49 6221 4294830
Dr. Camille Lowy
Senior scientist / project manager
Phone: +49 6221 4294830
Dr. Ronny Schmidt
Head of Contract Research
Phone: +49 6221 4294830

Products and services

  • COVID-19: Protein biomarkers for predicting a severe disease from plasma or serum

  • Acute Kidney Injury: Biomarker signature for prediction and early diagnosis in a peri-operative setting

  • scioDiscover: High-content protein profiling for 1,300 proteins in parallel.

The scioDiscover sample-to-result service is used by our customers from pharmaceutical industry and in biomedical research centres for Target discover & verification, Biomarker discovery & verification, Mode of action analysis, Early toxicology, Pathway profiling, Cell line / animal model selection & control

  • scioPhospho & scioUbi: High-content analysis of phosphorylation or ubiquitination status and protein abundance for 1,300 proteins in parallel.

  • scioCD: Protein profiling of 119 cytokines / chemokine and 141 cell surface markers in a single assay. This analysis is ideally suitiable to profile the immune response to external stimuli.
scioUbi

scioUbi is a high-content protein expression and ubiquitination level analysis.
With scioUbi you can analyse up to 1,300 proteins in a single assay.

Further reading

scioPhospho

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation.

Further reading

scioCD

Protein profiling of 119 cytokines / chemokine and 141 cell surface markers in a single assay. This analysis is ideally suitiable to profile the immune response to external stimuli.

Further reading

News & Innovations

Acute Kidney Injury: Biomarker signature for prediction and early diagnosis of peri-operative AKI
COVID-19: Protein biomarkers for predicting a severe disease from plasma or serum

Click here if you notice an image that violates copyright or privacy rights.

Get in contact
OK

We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection